Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium.

Vaughn CB, Kavak KS, Dwyer MG, Bushra A, Nadeem M, Cookfair DL, Ramanathan M, Benedict RH, Zivadinov R, Goodman A, Krupp L, Motl RW, Weinstock-Guttman B; New York State Multiple Sclerosis Consortium.

Mult Scler. 2018 Dec 3:1352458518816619. doi: 10.1177/1352458518816619. [Epub ahead of print]

PMID:
30507270
2.

Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk.

Gaindh D, Kavak KS, Teter B, Vaughn CB, Cookfair D, Hahn T, Weinstock-Guttman B; New York State Multiple Sclerosis Consortium.

J Neurol Sci. 2016 Nov 15;370:13-17. doi: 10.1016/j.jns.2016.09.005. Epub 2016 Sep 9.

PMID:
27772741
3.

Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC).

Zivadinov R, Cookfair DL, Krupp L, Miller AE, Lava N, Coyle PK, Goodman AD, Jubelt B, Lenihan M, Herbert J, Gottesman M, Snyder DH, Apatoff BR, Teter BE, Perel AB, Munschauer F, Weinstock-Guttman B.

BMC Neurol. 2016 Jul 15;16:102. doi: 10.1186/s12883-016-0623-2.

4.

Disclosure of disease status among employed multiple sclerosis patients: association with negative work events and accommodations.

Frndak SE, Kordovski VM, Cookfair D, Rodgers JD, Weinstock-Guttman B, Benedict RH.

Mult Scler. 2015 Feb;21(2):225-34. doi: 10.1177/1352458514540971. Epub 2014 Jul 28.

PMID:
25070678
5.

Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study.

Morrow SA, Smerbeck A, Patrick K, Cookfair D, Weinstock-Guttman B, Benedict RH.

J Neurol. 2013 Feb;260(2):489-97. doi: 10.1007/s00415-012-6663-7. Epub 2012 Sep 23.

PMID:
23001556
6.

Cancer mortality following radiotherapy for benign gynecologic disorders.

Sakata R, Kleinerman RA, Mabuchi K, Stovall M, Smith SA, Weathers R, Wactawski-Wende J, Cookfair DL, Boice JD Jr, Inskip PD.

Radiat Res. 2012 Oct;178(4):266-79. Epub 2012 Aug 2.

7.

Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients.

Weinstock-Guttman B, Zivadinov R, Qu J, Cookfair D, Duan X, Bang E, Bergsland N, Hussein S, Cherneva M, Willis L, Heininen-Brown M, Ramanathan M.

J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):189-95. doi: 10.1136/jnnp.2010.227942. Epub 2010 Nov 3.

PMID:
21047880
8.

Cognitive reserve moderates decline in information processing speed in multiple sclerosis patients.

Benedict RH, Morrow SA, Weinstock Guttman B, Cookfair D, Schretlen DJ.

J Int Neuropsychol Soc. 2010 Sep;16(5):829-35. doi: 10.1017/S1355617710000688. Epub 2010 Jul 8.

PMID:
20609273
9.

Glatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis. A case-control diffusion imaging study.

Zivadinov R, Hussein S, Stosic M, Durfee J, Cox JL, Hashmi K, Abdelrahman N, Garg N, Dwyer MG, Weinstock-Guttman B.

Pathophysiology. 2011 Feb;18(1):61-8. doi: 10.1016/j.pathophys.2010.04.007. Epub 2010 May 26. Erratum in: Pathophysiology. 2011 Sep;18(4):335. Cookfair, Diane L [removed].

PMID:
20510590
10.

Validity of the California Verbal Learning Test-II in multiple sclerosis.

Stegen S, Stepanov I, Cookfair D, Schwartz E, Hojnacki D, Weinstock-Guttman B, Benedict RH.

Clin Neuropsychol. 2010 Feb;24(2):189-202. doi: 10.1080/13854040903266910. Epub 2009 Nov 26.

PMID:
19953426
11.

Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study.

Horakova D, Cox JL, Havrdova E, Hussein S, Dolezal O, Cookfair D, Dwyer MG, Seidl Z, Bergsland N, Vaneckova M, Zivadinov R.

J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):407-14. Epub 2007 Jun 5.

PMID:
17550987
12.

Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.

Zivadinov R, Locatelli L, Cookfair D, Srinivasaraghavan B, Bertolotto A, Ukmar M, Bratina A, Maggiore C, Bosco A, Grop A, Catalan M, Zorzon M.

Mult Scler. 2007 May;13(4):490-501. Epub 2007 Feb 9.

PMID:
17463072
13.

Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS).

Benedict RH, Cookfair D, Gavett R, Gunther M, Munschauer F, Garg N, Weinstock-Guttman B.

J Int Neuropsychol Soc. 2006 Jul;12(4):549-58.

PMID:
16981607
14.

Semi-automatic brain region extraction (SABRE) reveals superior cortical and deep gray matter atrophy in MS.

Carone DA, Benedict RH, Dwyer MG, Cookfair DL, Srinivasaraghavan B, Tjoa CW, Zivadinov R.

Neuroimage. 2006 Jan 15;29(2):505-14. Epub 2005 Oct 5.

PMID:
16169253
15.

The role of the surgeon in quality cancer care.

Edge SB, Cookfair DL, Watroba N.

Curr Probl Surg. 2003 Sep;40(9):511-90. Review. No abstract available.

PMID:
12942052
16.

Interferons in relapsing remitting multiple sclerosis.

Rudick RA, Cookfair DL, Griffin J, Hauser S, Piantadosi S.

Lancet. 2003 May 24;361(9371):1824; author reply 1824-5. No abstract available.

PMID:
12781561
17.

Predictive immunophenotypes: disease-related profile in chronic fatigue syndrome.

Stewart CC, Cookfair DL, Hovey KM, Wende KE, Bell DS, Warner CL.

Cytometry B Clin Cytom. 2003 May;53(1):26-33.

18.

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997.

Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Granger CV, Simon JH, Alam JJ, Simonian NA, Campion MK, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Weistock-Guttman B, Whitham RH; Multiple Sclerosis Collaborative Research Group.

Neurology. 2001 Dec;57(12 Suppl 5):S25-30. No abstract available.

PMID:
11902591
19.

Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group.

Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Goodkin DE, Granger CV, Simon JH, Grafman JH, Lezak MD, O'Reilly Hovey KM, Perkins KK, Barilla-Clark D, Schacter M, Shucard DW, Davidson AL, Wende KE, Bourdette DN, Kooijmans-Coutinho MF.

Ann Neurol. 2000 Dec;48(6):885-92.

PMID:
11117545
20.

A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group.

Simon JH, Lull J, Jacobs LD, Rudick RA, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Sheeder J, Miller D, McCabe K, Serra A, Campion MK, Fischer JS, Goodkin DE, Simonian N, Lajaunie M, Wende K, Martens-Davidson A, Kinkel RP, Munschauer FE 3rd.

Neurology. 2000 Jul 25;55(2):185-92.

PMID:
10908888
21.

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

Simon JH, Jacobs LD, Campion MK, Rudick RA, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Simonian N, Lajaunie M, Miller DE, Wende K, Martens-Davidson A, Kinkel RP, Munschauer FE 3rd, Brownscheidle CM.

Neurology. 1999 Jul 13;53(1):139-48.

PMID:
10408550
23.

Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, Jacobs LD, Herndon RM, Salazar AM, Fischer JS, Granger CV, Goodkin DE, Simon JH, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munchsauer FE, O'Reilly K, Priore RL, Whitham RH, et al.

J Neuroimmunol. 1999 Jan 1;93(1-2):8-14.

PMID:
10378864
24.

Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E.

Brain. 1999 May;122 ( Pt 5):871-82.

PMID:
10355672
25.

Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG).

Goodkin DE, Priore RL, Wende KE, Campion M, Bourdette DN, Herndon RM, Fischer JS, Jacobs LD, Cookfair DL, Rudick RA, Richert JR, Salazar AM, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Whitham RH, et al.

Mult Scler. 1998 Dec;4(6):480-6.

PMID:
9987756
26.

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock-Guttman B, Herndon RM, Mass MK, Richert JR, Salazar AM, Munschauer FE 3rd, Cookfair DL, Simon JH, Jacobs LD.

Neurology. 1998 May;50(5):1266-72.

PMID:
9595973
27.

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Alam JJ, Fischer JS, Goodkin DE, Granger CV, Lajaunie M, Martens-Davidson AL, Meyer M, Sheeder J, Choi K, Scherzinger AL, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Whitham RH, et al.

Ann Neurol. 1998 Jan;43(1):79-87.

PMID:
9450771
28.

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Granger CV, Simon JH, Alam JJ, Simonian NA, Campion MK, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Whitham RH, et al.

Neurology. 1997 Aug;49(2):358-63.

PMID:
9270562
29.

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al.

Ann Neurol. 1996 Mar;39(3):285-94. Erratum in: Ann Neurol 1996 Sep;40(3):480.

PMID:
8602746
30.
31.

Chromosome aberrations in lymphocytes from women irradiated for benign and malignant gynecological disease.

Kleinerman RA, Littlefield LG, Tarone RE, Sayer AM, Cookfair DL, Wactawski-Wende J, Inskip PD, Block A, Ramesh KH, Boice JD Jr.

Radiat Res. 1994 Jul;139(1):40-6.

PMID:
8016306
32.

Serum estrogen and androgen levels following treatment for cervical cancer.

Inskip PD, Eby NL, Cookfair D, Freedman RS, Richardson GS, Wactawski-Wende J, Hoover RN, Boice JD Jr.

Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):37-45.

33.

In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta.

Rudick RA, Carpenter CS, Cookfair DL, Tuohy VK, Ransohoff RM.

Neurology. 1993 Oct;43(10):2080-7.

PMID:
8105424
34.

Leukemia, lymphoma, and multiple myeloma after pelvic radiotherapy for benign disease.

Inskip PD, Kleinerman RA, Stovall M, Cookfair DL, Hadjimichael O, Moloney WC, Monson RR, Thompson WD, Wactawski-Wende J, Wagoner JK, et al.

Radiat Res. 1993 Jul;135(1):108-24.

PMID:
8327655
35.

Circulating CD3+ CD4+ CD8+ T lymphocytes in multiple sclerosis.

Munschauer FE, Stewart C, Jacobs L, Kaba S, Ghorishi Z, Greenberg SJ, Cookfair D.

J Clin Immunol. 1993 Mar;13(2):113-8.

PMID:
8100570
36.

Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group.

Goodkin DE, Cookfair D, Wende K, Bourdette D, Pullicino P, Scherokman B, Whitham R.

Neurology. 1992 Apr;42(4):859-63.

PMID:
1565242
37.

Risk factors associated with chronic fatigue syndrome in a cluster of pediatric cases.

Bell KM, Cookfair D, Bell DS, Reese P, Cooper L.

Rev Infect Dis. 1991 Jan-Feb;13 Suppl 1:S32-8.

PMID:
2020801
38.

Timing of prenatal care and risk of sudden infant death syndrome.

Buck GM, Cookfair DL, Michalek AM, Nasca PC, Standfast SJ, Sever LE.

Int J Epidemiol. 1990 Dec;19(4):991-6.

PMID:
2084033
39.

Intrauterine growth retardation and risk of sudden infant death syndrome (SIDS)

Buck GM, Cookfair DL, Michalek AM, Nasca PC, Standfast SJ, Sever LE, Kramer AA.

Am J Epidemiol. 1989 May;129(5):874-84.

PMID:
2705432
40.

Assessment of in utero hypoxia and risk of sudden infant death syndrome.

Buck GM, Cookfair DL, Michalek AM, Nasca PC, Standfast SJ, Sever LE.

Paediatr Perinat Epidemiol. 1989 Apr;3(2):157-73.

PMID:
2734234
41.

Radiation dose and second cancer risk in patients treated for cancer of the cervix.

Boice JD Jr, Engholm G, Kleinerman RA, Blettner M, Stovall M, Lisco H, Moloney WC, Austin DF, Bosch A, Cookfair DL, Krementz ET, Latourette HB, Merrill JA, Peters LJ, Schulz MD, Storm HH, Bjorkholm E, Pettersson F, Janine Bell CM, Coleman MP, Fraser P, Neal FE, Prior P, Choi NW, Hislop TG, Koch M, Kreiger N, Robb D, Robson D, Thomson DH, Lochmuller H, von Fournier D, Frischkorn R, Kjørstad KE, Rimpela A, Pejovic MH, Kirn VP, Stankusova H, Berrino F, Sigurdsson K, Hutchison GB, MacMahon B.

Radiat Res. 1988 Oct;116(1):3-55.

PMID:
3186929
42.

Radiation dose and leukemia risk in patients treated for cancer of the cervix.

Boice JD Jr, Blettner M, Kleinerman RA, Stovall M, Moloney WC, Engholm G, Austin DF, Bosch A, Cookfair DL, Krementz ET, Latourette HB, Peters LJ, Schulz MD, Lundell M, Pettersson F, Storm HH, Bell CM, Coleman MP, Fraser P, Palmer M, Prior P, Choi NW, Hislop TG, Koch M, Robb D, Robson D, Spengler RF, von Fournier D, Frischkorn R, Lochmüller H, Pompe-Kirn V, Rimpela A, Kjørstad K, Pejovic MH, Sigurdsson K, Pisani P, Kucera H, Hutchison GB.

J Natl Cancer Inst. 1987 Dec;79(6):1295-311.

PMID:
3480381
43.

Mortality of a municipal worker cohort: II. Females.

Vena JE, Cookfair DL, Fiedler RC, Barnes RE.

Am J Ind Med. 1986;9(2):159-69.

PMID:
3962997
44.
45.

Occupation and lung cancer risk. An analysis by histologic subtypes.

Vena JE, Byers TE, Cookfair D, Swanson M.

Cancer. 1985 Aug 15;56(4):910-7.

PMID:
2990660
46.

The quality of life in patients with cancer. A survey at one treatment center.

Mettlin C, Cookfair DL, Lane W, Pickren J.

N Y State J Med. 1983 Feb;83(2):187-93. No abstract available.

PMID:
6572806
47.

Quality of life among cancer patients.

Cookfair DL, Mettlin C, Cummings KM, Lane W.

Prog Clin Biol Res. 1983;120:445-53. No abstract available.

PMID:
6878302
48.

Lung cancers in butchers.

Vena JE, Byers T, Swanson M, Cookfair D.

Lancet. 1982 Sep 25;2(8300):713. No abstract available.

PMID:
6126645

Supplemental Content

Loading ...
Support Center